Centre Hospitalier Universitaire Vaudois
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Private
- Established
- 2008-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.chuv.ch
Immunotherapy of Stage III/IV Melanoma Patients
Phase 1
Completed
- Conditions
- Interventions
- Biological: Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpGBiological: Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpGBiological: Melan-A ELA + NY-ESO-1b + MAGE-A10 + MontanideBiological: Melan-A ELA + MontanideBiological: Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2
- First Posted Date
- 2005-06-01
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 39
- Registration Number
- NCT00112242
- Locations
- π¨π
Oncology Department, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Vaud, Switzerland
π¨πDivision of Oncology at the Geneva University Hospital, Geneva, Switzerland
Β© Copyright 2024. All Rights Reserved by MedPath